EP0624192A1 - Nouvelles tyrosine kinases de proteines - Google Patents

Nouvelles tyrosine kinases de proteines

Info

Publication number
EP0624192A1
EP0624192A1 EP93903639A EP93903639A EP0624192A1 EP 0624192 A1 EP0624192 A1 EP 0624192A1 EP 93903639 A EP93903639 A EP 93903639A EP 93903639 A EP93903639 A EP 93903639A EP 0624192 A1 EP0624192 A1 EP 0624192A1
Authority
EP
European Patent Office
Prior art keywords
seq
lptk
bptk
protein
sal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93903639A
Other languages
German (de)
English (en)
Inventor
Hava Avraham
Jerome Groopman
Sally Cowley
David Scadden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
New England Deaconess Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Deaconess Hospital filed Critical New England Deaconess Hospital
Publication of EP0624192A1 publication Critical patent/EP0624192A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à l'identification et à l'isolation de nouvelles tyrosine kinases de protéines présentes en tant que gènes sur des cellules mégakaryocytiques et lymphocytiques humaines, aux protéines codées par ces gènes, à des anticorps spécifiques de ces protéines codées, à des séquences d'acides nucléiques ARN qui s'hybrident avec ces gènes et à des procédés d'utilisation correspondants.
EP93903639A 1992-01-22 1993-01-22 Nouvelles tyrosine kinases de proteines Withdrawn EP0624192A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82693592A 1992-01-22 1992-01-22
US826935 1992-01-22
PCT/US1993/000586 WO1993015201A1 (fr) 1992-01-22 1993-01-22 Nouvelles tyrosine kinases de proteines

Publications (1)

Publication Number Publication Date
EP0624192A1 true EP0624192A1 (fr) 1994-11-17

Family

ID=25247892

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93903639A Withdrawn EP0624192A1 (fr) 1992-01-22 1993-01-22 Nouvelles tyrosine kinases de proteines

Country Status (5)

Country Link
EP (1) EP0624192A1 (fr)
JP (1) JPH07504813A (fr)
AU (1) AU3482493A (fr)
CA (1) CA2128722A1 (fr)
WO (1) WO1993015201A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) * 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
WO1995006113A1 (fr) * 1993-08-25 1995-03-02 Asahi Kasei Kogyo Kabushiki Kaisha Nouvelle tyrosine kinase
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
US5834441A (en) * 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US6287784B1 (en) 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
CA2175893C (fr) * 1993-11-23 2010-06-22 Paul J. Godowski Tyrosine kinases proteiques appelees rse
AU698975B2 (en) * 1993-11-23 1998-11-12 Genentech Inc. Kinase receptor activation assay
US6001621A (en) * 1993-11-23 1999-12-14 Genetech, Inc. Protein tyrosine kinases
JP3665071B2 (ja) * 1993-12-02 2005-06-29 旭化成株式会社 新規なリセプター型チロシンキナーゼ
US6506578B1 (en) * 1994-04-22 2003-01-14 Sugen, Inc. Nucelotide encoding megakaryocytic protein tyrosine kinases
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
US5624899A (en) * 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand
EP1353952B1 (fr) 1994-11-14 2007-04-11 Ludwig Institute For Cancer Research Flt4 (vegfr-3) utilise comme cible pour l'imagerie des tumeurs et le traitement antitumoral
WO1996026958A2 (fr) * 1995-02-27 1996-09-06 President And Fellows Of Harvard College L'elf-2, ligand du recepteur eph
US6531296B1 (en) * 1995-06-20 2003-03-11 The University Of North Carolina At Chapel Hill Nuclear tyrosine kinase Rak
JPH11514976A (ja) 1995-09-08 1999-12-21 ジェネンテク・インコーポレイテッド Ｖｅｇｆ−関連タンパク質
US5981201A (en) 1997-01-08 1999-11-09 Beth Israel Deaconess Medical Center Methods of detection and treatment of breast cancer
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
WO2000021560A1 (fr) 1998-10-09 2000-04-20 Ludwig Institute For Cancer Research Flt4 (vegfr-3) servant de cible dans l'imagerie de tumeurs et la therapie antitumorale
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2004080425A2 (fr) 2003-03-12 2004-09-23 Vasgene Therapeutics, Inc. Composes polypeptidiques permettant d'inhiber l'angiogenese et la croissance tumorale
ATE411395T1 (de) * 2003-10-24 2008-10-15 Oncalis Ag Verfahren zur identifizierung und/oder validierung von rezeptortyrosinkinase-inhibitoren
KR20120123619A (ko) 2004-03-12 2012-11-08 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
EP2275445A3 (fr) 2004-03-12 2012-02-29 Vasgene Therapeutics, Inc. Anticorps anti-ephb4 pour inhiber l'angiogenese et la croissance tumorale
JP5219513B2 (ja) 2004-09-23 2013-06-26 バスジーン セラピューティクス，インコーポレイテッド 血管形成及び腫瘍増殖阻害用ポリペプチド化合物
BRPI0815399A2 (pt) 2007-08-13 2019-09-24 Vasgene Therapeutics Inc tratamento de câncer usando anticorpos humanizados que se ligam ephb4
CA3154024C (fr) 2010-06-03 2024-02-27 Pharmacyclics Llc Utilisation d'inhibiteurs de la tyrosine-kinase de bruton dans le traitement du lymphome folliculaire en retour ou refractaire
NZ710658A (en) 2013-02-18 2019-12-20 Vegenics Pty Ltd Ligand binding molecules and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0536350B1 (fr) * 1991-02-22 2002-08-07 American Cyanamid Company Identification d'un nouveau gene humain recepteur de tyrosine kinase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9315201A1 *

Also Published As

Publication number Publication date
AU3482493A (en) 1993-09-01
CA2128722A1 (fr) 1993-08-05
WO1993015201A1 (fr) 1993-08-05
JPH07504813A (ja) 1995-06-01

Similar Documents

Publication Publication Date Title
EP0624192A1 (fr) Nouvelles tyrosine kinases de proteines
JP3193301B2 (ja) 生理活性タンパク質ｐ１６０
Damen et al. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3, 4, 5-triphosphate 5-phosphatase.
Wong et al. A protein-binding domain, EH, identified in the receptor tyrosine kinase substrate Eps15 and conserved in evolution.
Beck et al. The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus
Sanchez et al. Multiple tyrosine protein kinases in rat hippocampal neurons: isolation of Ptk-3, a receptor expressed in proliferative zones of the developing brain.
US6255472B1 (en) Isolated nucleic acid molecule encoding a human skeletal muscle-specific receptor
Cai et al. AND-34, a novel p130Cas-binding thymic stromal cell protein regulated by adhesion and inflammatory cytokines
Brown et al. Molecular characterization of the zebrafish PEA3 ETS-domain transcription factor
US6242253B1 (en) IkB kinase, subunits thereof, and methods of using same
AU2001263952B2 (en) Tumour suppressor and uses thereof
JP4125379B2 (ja) ＩκＢキナーゼ、そのサブユニット、およびこれらを使用する方法
Ito et al. The Runt domain transcription factor, PEBP2/CBF, and its involvement in human leukemia
JP2005519584A5 (fr)
Gardner et al. Cloning, characterization, and chromosomal localization of Pnck, a Ca2+/calmodulin-dependent protein kinase
Ogawa et al. Molecular cloning of a novel RING finger-B box-coiled coil (RBCC) protein, terf, expressed in the testis
Kunita et al. Identification and characterization of novel members of the CREG family, putative secreted glycoproteins expressed specifically in brain
JPH09502866A (ja) セリントレオニンキナーゼ族の新規一員のクローニング
WO1997045542A2 (fr) Genes regulateurs de la croissance cellulaire
Suriyapperuma et al. The mouse adducin gene family: alternative splicing and chromosomal localization
Ishino et al. Identification of an Efs isoform that lacks the SH3 domain and chromosomal mapping of human Efs
Park Cloning, sequencing, and overexpression of SH2/SH3 adaptor protein Nck from mouse thymus
US6803204B2 (en) Biologically active alternative form of the IKKα IκB kinase
WO1999001559A1 (fr) Nouvelle kinase mapk
Hughes et al. Cloning and Chromosomal Localization of a Mouse cDNA with Homology to theSaccharomyces cerevisiaeGene Zuotin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940729

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.

17Q First examination report despatched

Effective date: 20010125

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010606